Eckhart Weidmann

7.6k total citations · 1 hit paper
111 papers, 5.0k citations indexed

About

Eckhart Weidmann is a scholar working on Pathology and Forensic Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Eckhart Weidmann has authored 111 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pathology and Forensic Medicine, 36 papers in Immunology and 35 papers in Molecular Biology. Recurrent topics in Eckhart Weidmann's work include Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Immunotherapy and Immune Responses (17 papers). Eckhart Weidmann is often cited by papers focused on Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Immunotherapy and Immune Responses (17 papers). Eckhart Weidmann collaborates with scholars based in Germany, United States and United Kingdom. Eckhart Weidmann's co-authors include Lothar Bergmann, Dieter Hoelzer, Ulrich Maurer, Paris S. Mitrou, D. Hoelzer, Jürgen Brieger, Mathias Rummel, T. Karakas, Wolfram Brugger and Manfred Welslau and has published in prestigious journals such as Nature, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Eckhart Weidmann

110 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2013 962 citations Mathias Rummel, N. Niederle et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eckhart Weidmann Germany	38	2.1k	2.0k	1.4k	1.3k	1.3k	111	5.0k
Hartmut Kirchner Germany	32	1.7k 0.8×	1.9k 1.0×	1.3k 1.0×	1.2k 0.9×	826 0.6×	117	5.0k
Javier Briones Spain	35	1.3k 0.6×	1.9k 1.0×	831 0.6×	1.7k 1.3×	957 0.7×	161	4.5k
Thierry Lamy France	41	2.6k 1.2×	2.3k 1.2×	1.4k 1.0×	2.6k 2.0×	2.1k 1.6×	177	6.4k
Lubomir Sokol United States	37	2.0k 0.9×	1.8k 0.9×	1.3k 1.0×	1.4k 1.1×	1.4k 1.1×	269	5.3k
Dina Ben‐Yehuda Israel	35	1.4k 0.6×	1.3k 0.7×	2.1k 1.5×	579 0.4×	1.2k 0.9×	124	4.8k
Dominique Bordessoule France	39	2.3k 1.1×	2.2k 1.1×	1.3k 1.0×	1.1k 0.8×	1.9k 1.5×	188	6.3k
Kiyohiko Hatake Japan	41	1.1k 0.5×	2.3k 1.2×	1.3k 0.9×	1.2k 0.9×	741 0.6×	237	5.1k
Martin Gramatzki Germany	46	1.2k 0.5×	2.5k 1.3×	2.1k 1.5×	2.6k 2.0×	844 0.7×	207	6.8k
Gottfried Dölken Germany	32	1.4k 0.7×	1.3k 0.7×	864 0.6×	456 0.4×	867 0.7×	109	3.5k
Yoshitoyo Kagami Japan	35	2.3k 1.1×	1.9k 1.0×	739 0.5×	1.0k 0.8×	705 0.5×	102	3.9k

Countries citing papers authored by Eckhart Weidmann

Since Specialization

Citations

This map shows the geographic impact of Eckhart Weidmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eckhart Weidmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eckhart Weidmann more than expected).

Fields of papers citing papers by Eckhart Weidmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eckhart Weidmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eckhart Weidmann. The network helps show where Eckhart Weidmann may publish in the future.

Co-authorship network of co-authors of Eckhart Weidmann

This figure shows the co-authorship network connecting the top 25 collaborators of Eckhart Weidmann. A scholar is included among the top collaborators of Eckhart Weidmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eckhart Weidmann. Eckhart Weidmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rummel, Mathias, Ulrich Kaiser, Christina Balser, et al.. (2015). Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet Oncology. 17(1). 57–66. 110 indexed citations

Karbach, Julia, Sacha Gnjatic, Akin Atmaca, et al.. (2014). Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates. Cancer Immunology Research. 2(5). 404–409. 12 indexed citations

Bergmann, Lothar, Luise Maute, Gerhard Heil, et al.. (2014). A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer. European Journal of Cancer. 51(1). 27–36. 51 indexed citations

Weidmann, Eckhart, Antje Neumann, F. Fauth, et al.. (2011). Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Annals of Oncology. 22(8). 1839–1844. 65 indexed citations

Chow, Pierce K. H., Daniel Nowak, Sang Wook Kim, et al.. (2005). In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. Pharmacological Research. 53(1). 49–61. 13 indexed citations

Weidmann, Eckhart, Martin Gramatzki, Mathias Wilhelm, & P.S. Mitrou. (2004). Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting. Annals of Oncology. 15(3). 369–374. 3 indexed citations

Chow, Kai Uwe, Daniel Nowak, Simone Boehrer, et al.. (2003). Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochemical Pharmacology. 66(5). 711–724. 32 indexed citations

Schneider, Bernd, et al.. (2002). Inhibiting effects on the induction of cytotoxic T lymphocytes by dendritic cells pulsed with lysates from acute myeloid leukemia blasts. Leukemia Research. 26(4). 383–389. 17 indexed citations

Boehrer, Simone, et al.. (2002). Cytotoxic Activity of T- and NK-cell Lymphoma Cells is not Dependent on a Mature Cytotoxic Phenotype. Leukemia & lymphoma. 43(12). 2363–2368. 2 indexed citations

10.

Boehrer, Simone, Thomas Hinz, Svetlana Harder, et al.. (2001). T‐large granular lymphocyte leukaemia with natural killer cell‐like cytotoxicity and expression of two different α‐ and β‐T‐cell receptor chains. British Journal of Haematology. 112(1). 201–203. 9 indexed citations

11.

Fauth, F., et al.. (2001). AC133 expression on acute myeloid leukemia blasts: correlation to FAB and to CD34 expression and possible implications for peripheral blood progenitor cell purging in AML. Leukemia Research. 25(3). 191–196. 10 indexed citations

12.

Weidmann, Eckhart, Thomas Hinz, Svetlana Harder, et al.. (2000). Cytotoxic hepatosplenic gammadelta T-cell lymphoma following acute myeloid leukemia bearing two distinct gamma chains of the T-cell receptor. Biologic and clinical features.. PubMed. 85(10). 1024–31. 13 indexed citations

13.

Weidmann, Eckhart, et al.. (2000). Management of Renal Complications in Patients with Advanced Multiple Myeloma. Leukemia & lymphoma. 38(5-6). 513–519. 2 indexed citations

14.

Chow, Kai Uwe, Eckhart Weidmann, Simone Boehrer, et al.. (2000). Induction of apoptosis using 2′,2′difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Annals of Hematology. 79(9). 485–492. 27 indexed citations

15.

Klein, Stefan, Oliver G. Ottmann, Thomas S. Dobmeyer, et al.. (1999). QUANTIFICATION OF HUMAN INTERLEUKIN 18 mRNA EXPRESSION BY COMPETITIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION. Cytokine. 11(6). 451–458. 22 indexed citations

16.

Weidmann, Eckhart, Alexander Schmidt, Lothar Bergmann, et al.. (1999). The effects of interleukin‐2 treatment on endothelin and the activation of the hypothalamic–pituitary–adrenal axis. Clinical Endocrinology. 50(1). 37–44. 13 indexed citations

17.

Jahn, Bernhard, Lothar Bergmann, Eckhart Weidmann, et al.. (1995). Bone marrow-derived T-cell clones obtained from untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity. Leukemia Research. 19(2). 73–82. 24 indexed citations

18.

Weidmann, Eckhart, Jürgen Brieger, Bernhard Jahn, et al.. (1995). Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Annals of Hematology. 70(3). 153–158. 5 indexed citations

19.

Bergmann, Lothar, Eckhart Weidmann, Paris S. Mitrou, et al.. (1990). Interleukin-2 in Combination with Interferon-Alpha in Disseminated Malignant Melanoma and Advanced Renal Cell Carcinoma. Oncology Research and Treatment. 13(2). 137–140. 18 indexed citations

20.

Bergmann, Lothar, et al.. (1987). Impaired T- and B-cell functions in patients with Hodgkin's disease. Cancer Immunology Immunotherapy. 25(1). 59–64. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact